• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Application of Advanced Imaging to Prostate Cancer Diagnosis and Management: A Narrative Review of Current Practice and Unanswered Questions.先进成像技术在前列腺癌诊断与管理中的应用:当前实践及未解决问题的叙述性综述
J Clin Med. 2024 Jan 13;13(2):446. doi: 10.3390/jcm13020446.
2
The Impact of Positron Emission Tomography Imaging and Tumor Molecular Profiling on Risk Stratification, Treatment Choice, and Oncological Outcomes of Patients with Primary or Relapsed Prostate Cancer: An International Collaborative Review of the Existing Literature.正电子发射断层扫描成像和肿瘤分子谱分析对初发或复发前列腺癌患者风险分层、治疗选择和肿瘤学结局的影响:对现有文献的国际协作回顾。
Eur Urol Oncol. 2024 Feb;7(1):27-43. doi: 10.1016/j.euo.2023.06.002. Epub 2023 Jul 8.
3
A Prospective Comparison of F-prostate-specific Membrane Antigen-1007 Positron Emission Tomography Computed Tomography, Whole-body 1.5 T Magnetic Resonance Imaging with Diffusion-weighted Imaging, and Single-photon Emission Computed Tomography/Computed Tomography with Traditional Imaging in Primary Distant Metastasis Staging of Prostate Cancer (PROSTAGE).F-前列腺特异性膜抗原-1007 正电子发射断层扫描计算机断层扫描、全身 1.5T 磁共振成像弥散加权成像与传统成像单光子发射计算机断层扫描/计算机断层扫描在前列腺癌原发远处转移分期(PROSTAGE)中的前瞻性比较
Eur Urol Oncol. 2021 Aug;4(4):635-644. doi: 10.1016/j.euo.2020.06.012. Epub 2020 Jul 13.
4
More advantages in detecting bone and soft tissue metastases from prostate cancer using F-PSMA PET/CT.使用F-PSMA PET/CT检测前列腺癌骨和软组织转移方面有更多优势。
Hell J Nucl Med. 2019 Jan-Apr;22(1):6-9. doi: 10.1967/s002449910952. Epub 2019 Mar 7.
5
The Role of Magnetic Resonance Imaging and Positron Emission Tomography/Computed Tomography in the Primary Staging of Newly Diagnosed Prostate Cancer: A Systematic Review of the Literature.磁共振成像和正电子发射断层扫描/计算机断层扫描在新诊断前列腺癌的分期中的作用:文献的系统评价。
Eur Urol Oncol. 2021 Jun;4(3):370-395. doi: 10.1016/j.euo.2020.11.002. Epub 2020 Dec 4.
6
Utility of F-Fluciclovine PET/MRI for Staging Newly Diagnosed High-Risk Prostate Cancer and Evaluating Response to Initial Androgen Deprivation Therapy: A Prospective Single-Arm Pilot Study.F-氟代脱氧葡萄糖 PET/MRI 对新诊断高危前列腺癌分期和评估初始雄激素剥夺治疗反应的效用:一项前瞻性单臂先导研究。
AJR Am J Roentgenol. 2021 Sep;217(3):720-729. doi: 10.2214/AJR.20.24509. Epub 2020 Oct 14.
7
Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer-Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis.镓 68 前列腺特异性膜抗原正电子发射断层扫描在晚期前列腺癌中的应用——更新的诊断效用、敏感性、特异性和前列腺特异性膜抗原阳性病变的分布:系统评价和荟萃分析。
Eur Urol. 2020 Apr;77(4):403-417. doi: 10.1016/j.eururo.2019.01.049. Epub 2019 Feb 14.
8
Incorporating Prostate-specific Membrane Antigen Positron Emission Tomography in Management Decisions for Men with Newly Diagnosed or Biochemically Recurrent Prostate Cancer.将前列腺特异性膜抗原正电子发射断层扫描纳入新诊断或生化复发前列腺癌男性管理决策中。
Eur Urol. 2023 Jun;83(6):521-533. doi: 10.1016/j.eururo.2022.10.024. Epub 2022 Nov 18.
9
Stereotactic Body Radiation Therapy Salvage for Lymph Node Recurrent Prostate Cancer in the Era of PSMA PET Imaging.基于 PSMA PET 成像的时代,立体定向体部放射治疗挽救前列腺癌局部淋巴结复发。
Curr Urol Rep. 2023 Oct;24(10):471-476. doi: 10.1007/s11934-023-01174-5. Epub 2023 Jul 3.
10
New Clinical Indications for (18)F/(11)C-choline, New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging: A Systematic Review of the Literature.(18)F/(11)C-胆碱的新临床适应证、正电子发射断层扫描的新型示踪剂和用于前列腺癌分期的有前途的混合设备:文献系统评价。
Eur Urol. 2016 Jul;70(1):161-175. doi: 10.1016/j.eururo.2016.01.029. Epub 2016 Feb 2.

引用本文的文献

1
PSMA PET/CT for prostate cancer diagnosis: current applications and future directions.用于前列腺癌诊断的PSMA PET/CT:当前应用及未来方向
J Cancer Res Clin Oncol. 2025 May 4;151(5):155. doi: 10.1007/s00432-025-06184-z.
2
Editorial: PET/CT and MRI in prostate cancer.社论:前列腺癌中的PET/CT与MRI
Front Oncol. 2024 May 24;14:1421542. doi: 10.3389/fonc.2024.1421542. eCollection 2024.
3
Innovative Drug Modalities for the Treatment of Advanced Prostate Cancer.用于治疗晚期前列腺癌的创新药物模式
Diseases. 2024 May 2;12(5):87. doi: 10.3390/diseases12050087.

本文引用的文献

1
Radiographic Progression-Free Survival and Clinical Progression-Free Survival as Potential Surrogates for Overall Survival in Men With Metastatic Hormone-Sensitive Prostate Cancer.影像学无进展生存期和临床无进展生存期作为转移性激素敏感性前列腺癌男性总生存期的潜在替代指标
J Clin Oncol. 2024 Mar 20;42(9):1044-1054. doi: 10.1200/JCO.23.01535. Epub 2024 Jan 5.
2
Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology.《前列腺癌(第四版)》,2023 年,NCCN 肿瘤学临床实践指南。
J Natl Compr Canc Netw. 2023 Oct;21(10):1067-1096. doi: 10.6004/jnccn.2023.0050.
3
Diagnostic Performance and Safety of Positron Emission Tomography with F-rhPSMA-7.3 in Patients with Newly Diagnosed Unfavourable Intermediate- to Very-high-risk Prostate Cancer: Results from a Phase 3, Prospective, Multicentre Study (LIGHTHOUSE).F-rhPSMA-7.3 正电子发射断层扫描在初诊不利中高危前列腺癌患者中的诊断性能和安全性:一项 3 期前瞻性多中心研究(LIGHTHOUSE)的结果。
Eur Urol. 2023 Oct;84(4):361-370. doi: 10.1016/j.eururo.2023.06.018. Epub 2023 Jul 5.
4
Updates to Advanced Prostate Cancer: AUA/SUO Guideline (2023).《晚期前列腺癌更新:AUA/SUO 指南(2023)》。
J Urol. 2023 Jun;209(6):1082-1090. doi: 10.1097/JU.0000000000003452. Epub 2023 Apr 25.
5
Cancer statistics, 2023.癌症统计数据,2023 年。
CA Cancer J Clin. 2023 Jan;73(1):17-48. doi: 10.3322/caac.21763.
6
Long axial field-of-view PET/CT devices: are we ready for the technological revolution?长轴视野PET/CT设备:我们是否已为这场技术革命做好准备?
Expert Rev Med Devices. 2022 Oct;19(10):739-743. doi: 10.1080/17434440.2022.2141111. Epub 2022 Oct 31.
7
Inter-reader agreement of the prostate imaging reporting and data system version v2.1 for detection of prostate cancer: A systematic review and meta-analysis.前列腺影像报告和数据系统v2.1版在前列腺癌检测方面的阅片者间一致性:一项系统评价和荟萃分析
Front Oncol. 2022 Sep 29;12:1013941. doi: 10.3389/fonc.2022.1013941. eCollection 2022.
8
Diagnostic yield of multiparametric MRI for local recurrence at biochemical recurrence after radical prostatectomy.多参数磁共振成像对前列腺癌根治术后生化复发时局部复发的诊断价值
Prostate Int. 2022 Sep;10(3):135-141. doi: 10.1016/j.prnil.2022.05.001. Epub 2022 May 12.
9
Radiomics and artificial intelligence in prostate cancer: new tools for molecular hybrid imaging and theragnostics.前列腺癌的放射组学和人工智能:分子混合成像和治疗的新工具。
Eur Radiol Exp. 2022 Jun 15;6(1):27. doi: 10.1186/s41747-022-00282-0.
10
Alternative- and focal therapy trends for prostate cancer: a total population analysis of in-patient treatments in Germany from 2006 to 2019.前列腺癌的替代和焦点治疗趋势:2006 年至 2019 年德国住院治疗的全人群分析。
World J Urol. 2022 Jul;40(7):1645-1652. doi: 10.1007/s00345-022-04024-0. Epub 2022 May 13.

先进成像技术在前列腺癌诊断与管理中的应用:当前实践及未解决问题的叙述性综述

Application of Advanced Imaging to Prostate Cancer Diagnosis and Management: A Narrative Review of Current Practice and Unanswered Questions.

作者信息

McKone Elizabeth L, Sutton Elsa A, Johnson Geoffrey B, Phillips Ryan M

机构信息

Department of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA.

Department of Radiology, Nuclear Medicine Division, Mayo Clinic, Rochester, MN 55905, USA.

出版信息

J Clin Med. 2024 Jan 13;13(2):446. doi: 10.3390/jcm13020446.

DOI:10.3390/jcm13020446
PMID:38256579
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10816977/
Abstract

Major advances in prostate cancer diagnosis, staging, and management have occurred over the past decade, largely due to our improved understanding of the technical aspects and clinical applications of advanced imaging, specifically magnetic resonance imaging (MRI) and prostate-cancer-specific positron emission tomography (PET). Herein, we review the established utility of these important and exciting technologies, as well as areas of controversy and uncertainty that remain important areas for future study. There is strong evidence supporting the utility of MRI in guiding initial biopsy and assessing local disease. There is debate, however, regarding how to best use the imaging modality in risk stratification, treatment planning, and assessment of biochemical failure. Prostate-cancer-specific PET is a relatively new technology that provides great value to the evaluation of newly diagnosed, treated, and recurrent prostate cancer. However, its ideal use in treatment decision making, staging, recurrence detection, and surveillance necessitates further research. Continued study of both imaging modalities will allow for an improved understanding of their best utilization in improving cancer care.

摘要

在过去十年中,前列腺癌的诊断、分期和管理取得了重大进展,这主要归功于我们对先进成像技术(特别是磁共振成像(MRI)和前列腺癌特异性正电子发射断层扫描(PET))的技术层面和临床应用有了更深入的了解。在此,我们回顾这些重要且令人兴奋的技术已确立的效用,以及仍作为未来研究重要领域的争议和不确定领域。有强有力的证据支持MRI在指导初始活检和评估局部疾病方面的效用。然而,关于如何在风险分层、治疗规划和生化失败评估中最佳使用这种成像方式存在争议。前列腺癌特异性PET是一项相对较新的技术,它为新诊断、治疗和复发性前列腺癌的评估提供了巨大价值。然而,其在治疗决策、分期、复发检测和监测中的理想应用需要进一步研究。对这两种成像方式的持续研究将有助于更好地理解它们在改善癌症治疗中的最佳利用方式。